Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

33.77
+0.03500.10%
Volume:31.84K
Turnover:1.08M
Market Cap:2.96B
PE:-18.52
High:34.33
Open:33.87
Low:33.72
Close:33.73
52wk High:37.08
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.52
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8227
EPS(LYR):-3.3605
ROE:-14.15%
ROA:-10.77%
PB:2.71
PE(LYR):-10.05

Loading ...

IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy Rating

TIPRANKS
·
Oct 24

IDEAYA Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
Oct 24

U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic

Reuters
·
Oct 23

Mizuho Securities Remains a Buy on IDEAYA Biosciences (IDYA)

TIPRANKS
·
Oct 22

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA) and Rani Therapeutics Holdings (RANI)

TIPRANKS
·
Oct 21

RBC Raises Price Target on IDEAYA Biosciences to $41 From $38, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Oct 21

IDEAYA Biosciences Price Target Maintained With a $62.00/Share by BTIG

Dow Jones
·
Oct 21

Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)

TIPRANKS
·
Oct 21

U.S. RESEARCH ROUNDUP-Block, Morgan Stanley, W R Berkley

Reuters
·
Oct 21

Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials

TIPRANKS
·
Oct 21

IDEAYA Biosciences Presents Promising Phase 2 Data

TIPRANKS
·
Oct 21

BUZZ-U.S. STOCKS ON THE MOVE-Arm Holdings, silver miners, Zions Bancorp

Reuters
·
Oct 21

IDEAYA Biosciences Shares Rise 2.3% After Co's Drug Combo Shows Survival Benefit in Rare Eye Cancer Trial

THOMSON REUTERS
·
Oct 20

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Planet Labs, WW International

Reuters
·
Oct 20

BUZZ-Ideaya rises as drug combo shows survival benefit in rare eye cancer trial

Reuters
·
Oct 20

Ideaya Biosciences presents clinical data from OptimUM-09 trial

TIPRANKS
·
Oct 20

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at Esmo 2025

THOMSON REUTERS
·
Oct 20

Ideaya Biosciences reports overall survival data from darovasertib trial

TIPRANKS
·
Oct 20

IDEAYA Biosciences Reports Darovasertib and Crizotinib Combo Doubles Survival in Metastatic Uveal Melanoma Trial

Reuters
·
Oct 20

IDEAYA Biosciences Inc - Darovasertib and Crizotinib Combination Shows 21.1 Months Median Overall Survival

THOMSON REUTERS
·
Oct 20